1. WHO Report on the Global Tobacco Epidemic, 2017 Geneva: World Health Organization; 2017 [Available from: https://www.who.int/tobacco/global_report/2017/en/.
2. Smoking the FACTS Dublin, Ireland: HSE; 2020 [Available from: https://www.hse.ie/eng/about/who/tobaccocontrol/kf/#:~:text=Tobacco%20use%20is%20the%20leading,(COPD)%20and%20heart%20disease.
3. Healthy Ireland Summary Report 2019 Ireland: Government Publications; 2019 [Available from: https://assets.gov.ie/41141/e5d6fea3a59a4720b081893e11fe299e.pdf.
4. Hosseinpoor AR, Parker LA, Tursan d'Espaignet E, Chatterji S. Socioeconomic inequality in smoking in low-income and middle-income countries: results from the World Health Survey. PLoS One. 2012;7(8):e42843.
5. Smith PH, Bessette AJ, Weinberger AH, Sheffer CE, McKee SA. Sex/gender differences in smoking cessation: A review. Preventive Medicine. 2016;92:135-40.
6. Cepeda-Benito A, Reynoso JT, Erath S. Meta-analysis of the efficacy of nicotine replacement therapy for smoking cessation: differences between men and women. J Consult Clin Psychol. 2004;72(4):712-22.
7. Fullerton D, Bauld L, Dobbie F. We Can Quit: findings from the action research study Dublin: Irish Cancer Society; 2015 [Available from: https://www.cancer.ie/sites/default/files/2019-11/we_can_quit_report_2015.pdf.
8. Andrews JO, Felton G, Ellen Wewers M, Waller J, Tingen M. The effect of a multi-component smoking cessation intervention in African American women residing in public housing. Res Nurs Health. 2007;30(1):45-60.
9. Andrews JO, Tingen MS, Jarriel SC, Caleb M, Simmons A, Brunson J, et al. Application of a CBPR framework to inform a multi-level tobacco cessation intervention in public housing neighborhoods. Am J Community Psychol. 2012;50(1-2):129-40.
10. Hayes C, Ciblis A, Darker C, Dougall N, Vance J, O'Connell N, et al. We Can Quit2 (WCQ2): a community-based intervention on smoking cessation for women living in disadvantaged areas of Ireland-study protocol for a pilot cluster randomised controlled trial. Pilot Feasibility Stud. 2019;5:138.
11. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis. 1967;20(8):637-48.
12. Treweek S, Zwarenstein M. Making trials matter: pragmatic and explanatory trials and the problem of applicability. Trials. 2009;10(1):37.
13. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ. 2015;350:h2147.
14. Courtright KR, Madden V, Gabler NB, Cooney E, Small DS, Troxel A, et al. Rationale and Design of the Randomized Evaluation of Default Access to Palliative Services (REDAPS) Trial. Ann Am Thorac Soc. 2016;13(9):1629-39.
15. Bullen C, Verbiest M, Galea-Singer S, Kurdziel T, Laking G, Newcombe D, et al. The effectiveness and safety of combining varenicline with nicotine e-cigarettes for smoking cessation in people with mental illnesses and addictions: study protocol for a randomised-controlled trial. BMC Public Health. 2018;18(1):596.
16. Coussement J, Kamar N, Matignon M, Weekers L, Scemla A, Giral M, et al. Antibiotics versus no therapy in kidney transplant recipients with asymptomatic bacteriuria (BiRT): a pragmatic, multicentre, randomized, controlled trial. Clin Microbiol Infect. 2021;27(3):398-405.
17. Horne J, Gilliland J, O'Connor C, Seabrook J, Hannaberg P, Madill J. Study protocol of a pragmatic randomized controlled trial incorporated into the Group Lifestyle Balance™ program: the nutrigenomics, overweight/obesity and weight management trial (the NOW trial). BMC Public Health. 2019;19(1):310.
18. Loudon K, Zwarenstein M, Sullivan FM, Donnan PT, Gágyor I, Hobbelen H, et al. The PRECIS-2 tool has good interrater reliability and modest discriminant validity. J Clin Epidemiol. 2017;88:113-21.
19. Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, et al. Process evaluation of complex interventions: Medical Research Council guidance. BMJ : British Medical Journal. 2015;350:h1258.
20. Clinical Trial Networks (CTN) 2021. Guidance Notes Ireland: HRB; 2021 [Available from: https://www.hrb.ie/fileadmin/2._Plugin_related_files/Funding_schemes/HRB_CTN_2021_Guidance_Notes_.pdf.
21. National Standard for Tobacco Cessation Support Programme Ireland: Health Service Executive; 2013 [Available from: https://www.hse.ie/eng/about/who/tobaccocontrol/cessation/tobaccocessationnationalstandard.pdf.
22. Ware J, Jr., Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220-33.
23. Weiner BJ, Lewis CC, Stanick C, Powell BJ, Dorsey CN, Clary AS, et al. Psychometric assessment of three newly developed implementation outcome measures. Implement Sci. 2017;12(1):108.
24. Dal-Ré R. Articles provided insufficient information to conduct an appropriate retrospective assessment of the pragmatic/explanatory features of medicine trials with the PRECIS-2 tool. Eur J Clin Pharmacol. 2020;76(8):1093-102.
25. Jordan AE, Perlman DC, Smith DJ, Reed JR, Hagan H. Use of the PRECIS-II instrument to categorize reports along the efficacy-effectiveness spectrum in an hepatitis C virus care continuum systematic review and meta-analysis. Journal of clinical epidemiology. 2018;93:66-75.
26. Palmer JA, Mor V, Volandes AE, McCreedy E, Loomer L, Carter P, et al. A dynamic application of PRECIS-2 to evaluate implementation in a pragmatic, cluster randomized clinical trial in two nursing home systems. Trials. 2018;19(1):453.
27. von Kaeppler EP, Donnelley C, Ali SH, Roberts HJ, Ibrahim JM, Wu H-H, et al. A study protocol for a Pilot Masked, Randomized Controlled Trial Evaluating Locally-applied Gentamicin versus Saline in Open Tibia Fractures (pGO-Tibia) in Dar es Salaam, Tanzania. Pilot and Feasibility Studies. 2021;7(1):47.
28. Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract. 2004;10(2):307-12.
29. Oude Rengerink K, Kalkman S, Collier S, Ciaglia A, Worsley SD, Lightbourne A, et al. Series: Pragmatic trials and real world evidence: Paper 3. Patient selection challenges and consequences. J Clin Epidemiol. 2017;89:173-80.
30. Gillies K, Kearney A, Keenan C, Treweek S, Hudson J, Brueton VC, et al. Strategies to improve retention in randomised trials. Cochrane Database of Systematic Reviews. 2021(3).
31. Neta G, Johnson KE. Informing real-world practice with real-world evidence: the value of PRECIS-2. BMC Medicine. 2018;16(1):76.
32. Smelt AF, van der Weele GM, Blom JW, Gussekloo J, Assendelft WJ. How usual is usual care in pragmatic intervention studies in primary care? An overview of recent trials. Br J Gen Pract. 2010;60(576):e305-18.
33. Nicholls SG, Zwarenstein M, Taljaard M. The Importance of Describing as Well as Defining Usual Care. Am J Bioeth. 2020;20(1):56-8.
34. Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. Bmj. 2008;337:a2390.
35. Burke S, Tomasone J, Scime NV, Ma JK, Harden S, Wolfe D. Physical activity sel† management interventions for adults with spinal cord injury: Part 2@ Exploring the generalizability of findings from research to practice Psychology of Sport and Exercise. 2017;37:28V 295.
36. Lipman PD, Loudon K, Dluzak L, Moloney R, Messner D, Stoney CM. Framing the conversation: use of PRECIS-2 ratings to advance understanding of pragmatic trial design domains. Trials. 2017;18(1):532.
37. Brody AA, Barnes DE, Chodosh J, Galvin JE, Hepburn KW, Troxel AB, et al. Building a National Program for Pilot Studies of Embedded Pragmatic Clinical Trials in Dementia Care. J Am Geriatr Soc. 2020;68 Suppl 2(Suppl 2):S14-s20.